Tauriga Sciences Inc. Granted 7 Day Extension by OTC Markets to Maintain Listing on OTCQB Exchange


NEW YORK, NY--(Marketwired - Jul 29, 2015) - Tauriga Sciences, Inc. (OTCQB: TAUG) or ("Tauriga" or the "Company"), a diversified life sciences company, today announced that is has been granted a 7 calendar day extension by OTC Markets to continue trading on the OTCQB exchange despite the Company's inability to file its Form 10-K for the year ended March 31, 2015 ("Form 10-K") with the Securities and Exchange Commission ("SEC") prior to 5:30 pm EDT today, July 29, 2015. If this extension had not been granted, Tauriga's common stock would have been moved to the OTC Pink Limited Information category at open of trading Thursday, July 30, 2015.

Currently, Tauriga has until 5:30 pm EDT on Wednesday, August 5, 2015 to file its Form 10-K with the SEC, otherwise OTC Markets will proceed to move the Company shares to the OTC Pink Limited Information category as discussed above unless granted an additional extension by the OTC Markets. The Company is taking all possible steps to file its Form 10-K prior to the August 5, 2015 deadline.

About TAURIGA SCIENCES, INC.:
Tauriga Sciences, Inc. (OTCQB: TAUG) is a diversified life sciences company focused on generating profitable revenues through its present and future holdings. The mission of the Company is to acquire and build a diversified portfolio of cutting edge technology assets that is capital efficient and of significant value to the shareholders. The Company's business model includes the acquisition of licenses, equity stakes, rights on both an exclusive and non-exclusive basis, and entire businesses. Management is firmly committed to building lasting shareholder value in the short, intermediate, and long terms. Please visit the Company's corporate website at www.tauriga.com

NON SOLICITATION:

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted. Any securities offered or issued in connection with the above-referenced merger and/or investment have not been registered, and will be offered pursuant to an exemption from registration.

DISCLAIMER:
Forward-Looking Statements: Except for statements of historical fact, this news release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on TAUG's predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which TAUG has little or no control. Such forward-looking statements are made only as of the date of this release, and TAUG assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by TAUG with the Securities and Exchange Commission. This press release does not and shall not constitute an offer to sell or the solicitation of any offer to buy any of the securities, nor shall there be any sale of the securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. The securities have not been registered under the Securities Act of 1933, as amended (the "Securities Act") or any state securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration, under the Securities Act and applicable state securities laws.

Food and Drug Administration Disclaimer: None of the statements contained in this press release regarding any of the products either offered or to be offered in the future by the Company have been evaluated by the Food and Drug Administration. Additionally, none of the products is intended to diagnose, treat, cure, or prevent any disease.

Contact Information:

CONTACT:
Mr. Seth M. Shaw
Chairman and Chief Executive Officer
Tauriga Sciences, Inc.
New York City: + 1-917-796-9926
Montreal: +1-514-840-3697
Email: sshaw@tauriga.com